Quantinno Capital Management LP Has $785,000 Stock Position in Mirum Pharmaceuticals, Inc. $MIRM

Quantinno Capital Management LP grew its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 166.2% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 8,497 shares of the company’s stock after acquiring an additional 5,305 shares during the period. Quantinno Capital Management LP’s holdings in Mirum Pharmaceuticals were worth $785,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of MIRM. Janus Henderson Group PLC lifted its holdings in Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after buying an additional 1,067,722 shares during the period. Vanguard Group Inc. increased its stake in shares of Mirum Pharmaceuticals by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock valued at $205,065,000 after buying an additional 50,720 shares during the period. State Street Corp raised its position in shares of Mirum Pharmaceuticals by 59.2% during the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after acquiring an additional 797,088 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Mirum Pharmaceuticals by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock worth $112,196,000 after acquiring an additional 137,087 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Mirum Pharmaceuticals by 56.6% in the fourth quarter. Wellington Management Group LLP now owns 1,237,830 shares of the company’s stock worth $97,776,000 after acquiring an additional 447,141 shares during the period.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $99.83 on Tuesday. The firm has a market cap of $6.48 billion, a PE ratio of -6.86 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 52-week low of $63.23 and a 52-week high of $130.00. The business’s 50 day moving average price is $111.04 and its two-hundred day moving average price is $102.03. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The company had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The business’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same period last year, the business earned ($0.12) EPS. On average, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.

Insider Activity

In related news, CEO Christopher Peetz sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $18,622,574.56. This represents a 13.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 2,721 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total value of $326,520.00. Following the completion of the transaction, the senior vice president owned 3,114 shares in the company, valued at approximately $373,680. The trade was a 46.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 93,156 shares of company stock worth $9,763,562. Company insiders own 8.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on MIRM shares. TD Cowen lowered their price target on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday. Morgan Stanley set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Robert W. Baird set a $123.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, August 6th. Finally, Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $137.33.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.